204 related articles for article (PubMed ID: 12067686)
21. Topoisomerases in human leukemia.
Peereboom D; Charron M; Kaufmann SH
Adv Pharmacol; 1994; 29B():33-50. PubMed ID: 8996600
[No Abstract] [Full Text] [Related]
22. Catalytic topoisomerase II inhibitors in cancer therapy.
Larsen AK; Escargueil AE; Skladanowski A
Pharmacol Ther; 2003 Aug; 99(2):167-81. PubMed ID: 12888111
[TBL] [Abstract][Full Text] [Related]
23. Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs.
Degrassi F; Fiore M; Palitti F
Curr Med Chem Anticancer Agents; 2004 Jul; 4(4):317-25. PubMed ID: 15281904
[TBL] [Abstract][Full Text] [Related]
24. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
25. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.
Skok Ž; Zidar N; Kikelj D; Ilaš J
J Med Chem; 2020 Feb; 63(3):884-904. PubMed ID: 31592646
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
27. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents.
Okoro CO; Fatoki TH
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768852
[TBL] [Abstract][Full Text] [Related]
28. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
30. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
32. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
Cancer Chemother Biol Response Modif; 1997; 17():114-31. PubMed ID: 9551211
[No Abstract] [Full Text] [Related]
33. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme.
Burden DA; Osheroff N
Biochim Biophys Acta; 1998 Oct; 1400(1-3):139-54. PubMed ID: 9748545
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
Holden JA
Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
[TBL] [Abstract][Full Text] [Related]
36. Iridoids as DNA topoisomerase I poisons.
Gálvez M; Martín-Cordero C; Ayuso MJ
J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
[TBL] [Abstract][Full Text] [Related]
37. Alchemix, p53 and topoisomerase.
Grand RJ; Stewart GS
Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618
[No Abstract] [Full Text] [Related]
38. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
[TBL] [Abstract][Full Text] [Related]
39. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Eder JP; Chan V; Wong J; Wong YW; Ara G; Northey D; Rizvi N; Teicher BA
Cancer Chemother Pharmacol; 1998; 42(4):327-35. PubMed ID: 9744779
[TBL] [Abstract][Full Text] [Related]
40. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.
Jensen LH; Renodon-Cornière A; Nitiss KC; Hill BT; Nitiss JL; Jensen PB; Sehested M
Biochem Pharmacol; 2003 Aug; 66(4):623-31. PubMed ID: 12906927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]